Rheumatoid arthritis, psoriasis, Crohn's disease — they're all driven by inflammation, and TNF (tumor necrosis factor) is a key culprit. TNF inhibitors block this molecule, calming the immune system. The TNF alpha inhibitors market report by MRFR shows that rheumatoid arthritis is the largest indication, but psoriasis is the fastest‑growing. The market is $22.28 billion and will hit $31.45 billion by 2035, growing at 3.14% CAGR — slow but steady, as biosimilars erode prices.

What's driving growth? Monoclonal antibodies (infliximab, adalimumab) are the largest drug class, but fusion proteins (etanercept) are the fastest‑growing. The TNF alpha inhibitors market analysis highlights that subcutaneous administration is the largest route, but intravenous is the fastest‑growing — for acute flares or when patients can't self‑inject.

What's new? Biosimilars (adalimumab biosimilars) are now widely available, cutting prices by 50‑80%. That's good for patients, but bad for originator companies.

The bottom line: TNF inhibitors are not new, but they're still the backbone of autoimmune therapy. If you have rheumatoid arthritis or psoriasis, they can be life‑changing.